AidaBreast™ Validates as Predictive Tool for Breast Cancer Radiotherapy Decisions

PreludeDx, a pioneering company in precision diagnostics for breast cancer, recently published a study in "Breast Cancer Research" on their AidaBreast™ test. This study marks a significant step forward in personalizing treatment for early-stage invasive breast cancer by predicting both locoregional recurrence risk and the potential benefit of radiation therapy.

AidaBreast™ distinguishes itself as the sole test leveraging multi-omic technology to provide these insights, offering data beyond conventional clinicopathologic features. This advancement reflects a growing trend toward biologically driven treatment decisions, as underscored by Dr. Naamit Gerber of NYU Langone Health's Perlmutter Cancer Center, who co-authored the study. Dr. Gerber emphasized that AidaBreast™ represents a critical move towards personalized cancer care.

The study involved 922 women with hormone receptor-positive, HER2-negative invasive breast cancer, each treated with breast-conserving surgery, with follow-ups extending to a median of 10 years. These participants were evaluated across numerous U.S. and Swedish institutions. AidaBreast™ integrates advanced RNA expression analysis with multiplex protein biomarkers and spatial biology to predict recurrence risks and assess radiation therapy benefits.

Dan Forche, President and CEO of PreludeDx, posited that the study solidifies AidaBreast™ as a benchmark in their commitment to precision diagnostics, aligning with their earlier work on DCISionRT, a tool for ductal carcinoma in situ (DCIS). Forche expressed that AidaBreast™ and DCISionRT highlight the company's dedication to advancing radiation therapy through personalized approaches.

Key aspects of the study indicate that AidaBreast™ effectively identifies patients with varying levels of radiotherapy benefits, informing decisions on whether to intensify or lessen treatment. This allows for a more tailored approach to radiation therapy, a critical consideration detailed by PreludeDx's Chief Scientific Officer, Troy Bremer, PhD, who notes the comprehensive tumor biology insights AidaBreast™ provides beyond standard clinicopathologic assessments.

In summary, as the field continues to push towards personalized medicine, the AidaBreast™ test presents a critical tool in bridging the gap between molecular data and clinical decision-making. It positions PreludeDx as a leader in personalized diagnostic solutions, broadening the scope of how early-stage invasive breast cancer can be managed effectively.